Promius Launches Promiseb Topical Cream

Promius has launched Promiseb Topical Cream, a non-steroidal, prescription only, cream for the treatment of seborrheic dermatitis, that has demonstrated both anti-inflammatory and antifungal properties.

Jeffrey Wasserstein, president of Promius, said: “We are very excited about Promiseb Cream because it has the potential to replace both anti-inflammatory and antifungal treatments in patients with seborrheic dermatitis.”

“In a clinical study Promiseb was shown to have efficacy comparable to desonide cream 0.05% at days 14 and 28 with fewer relapses. Promiseb Cream also has an excellent safety profile with no restrictions on age, duration of use or application on the face. We are very enthusiastic about this product because our clinical research shows that Promiseb Cream may be used as a first-line treatment for seborrheic flares and for long-term maintenance, he added.